Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field

Kyle LaHucik

Senior Reporter

Carbon Biosciences wants to disrupt the field of AAV gene therapy by tapping into a family of thousands of viruses to find ones that allow for the “next generation of viral delivery vehicles,” as CEO Joel Schneider puts it.

The Massachusetts biotech emerged Tuesday with $38 million in partnership with the Cystic Fibrosis Foundation to take a bocavirus-based — part of the broader parvovirus web — gene therapy into the clinic for the lung disorder.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Car­bon Bio­sciences emerges with a new vi­ral vec­tor to shake up the cys­tic fi­bro­sis gene ther­a­py field

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field

The next generation of AI biotechs is here. Can they deliver on the hype?

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Ophthalmic biotech raises $16.5M; Pfizer’s AI collaboration bears fruit

Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year